

Literatur

1. WHO. Obesity. Preventing and managing the global epidemic: report of a WHO consultation. World Health Organization, Geneva (2000)
2. Mensink GBM, Schienkiewitz A, Haftenberger M et al. (2013) Übergewicht und Adipositas in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitschutz 56: 786–794
3. Goebel R, Schulz M (2006) Nahrungsergänzungsmittel bei Übergewicht und Adipositas. Produkte mit hohem Beratungsbedarf. Pharmazie in unserer Zeit 35: 522–534
4. Gibson-Moore H (2010) Do slimming supplements work? Facts behind the headline. Nutrition Bulletin 35: 300–303
5. Heal DJ, Gosden J, Smith SL (2009) Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. BJCP 68: 861–874
6. Stephan K (2011) Wie sind Arzneimittel von anderen Gesundheitsprodukten abzugrenzen? Pharmazie in unserer Zeit 40: 300–304
7. BfArM – Medizinprodukte. URL: www.bfarm.de/DE/Medizinprodukte/_node.html Zugriff 13.04.16
8. Laux G, Dietmaier O. Psychopharmaka. Ein Ratgeber für Betroffene und Angehörige. 8., vollst. überarb. Aufl., Springer-Verlag, Berlin/Heidelberg (2009)
9. Deutschland. Sozialgesetzbuch (SGB) Fünftes Buch (V) – Gesetzliche Krankenversicherung 2016. (Artikel 1 des Gesetzes vom 20. Dezember 1988, BGBl. I S. 2477, 2482), das durch Artikel 6 des Gesetzes vom 10. Dezember 2015 (BGBl. I S. 2229) geändert worden ist. Stand: Zuletzt geändert durch Art. 2 G v. 1.12.2015., Publisher „Prospekt“ (2016)
10. Richtlinie des Gemeinsamen Bundesausschusses. Richtlinie über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung. (Arzneimittel-Richtlinie/AM-RL). in der Fassung vom 18. Dezember 2008/22. Januar 2009. URL: www.g-ba.de/downloads/62-492-1187/AM-RL_2016-02-18_iK-2016-06-01.pdf Zugriff 01.06.16
11. Jeukendrup AE, Randell R (2011) Fat burners. Nutrition supplements that increase fat metabolism. Obesity Reviews 12: 841–851
12. Hasani-Ranjbar S, Jouyandeh Z, Abdollahi M (2013) A systematic review of anti-obesity medicinal plants - an update. J Diabetes Metab Disord 12: 28
13. Rader JI, Delmonte P, Trucksess MW (2007) Recent studies on selected botanical dietary supplement ingredients. Analytical and bio-analytical chemistry 389: 27–35
14. Pittler MH, Ernst E (2004) Dietary supplements for body-weight reduction: a systematic review. AJCN 79: 529–536
15. Müller D, Weinmann W, Hermanns-Clausen M (2009) Sibutramin in chinesischen Schlankheitskapseln. Eine Fallserie. Deutsches Ärzteblatt 106: 218–222
16. Ebermann R, Elmadfa I. Lehrbuch Lebensmittelchemie und Ernährung. 2., korr. und erw. Aufl., Springer-Verlag, Vienna (2011)
17. Hänsel R, Sticher O. Pharmakognosie – Phytopharmazie. 9., überarb. und aktual. Aufl., Springer-Verlag, Berlin/Heidelberg (2010)
18. Haller D, Rimbach G, Grune T. Biofunktionalität der Lebensmittelinhaltsstoffe. Springer-Verlag, Berlin/Heidelberg (2013)
19. Birketvedt GS, Shimshi M, Erling T et al. (2005) Experiences with three different fiber supplements in weight reduction. Medical Science Monitor 11: 15–18
20. Walsh DE, Yaghoubian V, Behforooz A (1984) Effect of glucomannan on obese patients: a clinical study. Int J Obes 8: 289–293
21. Vido L, Facchin P, Antonello I et al. (1993) Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Pädiatrie und Pädologie 28: 133–136
22. Wood RJ, Fernandez ML, Sharman MJ et al. (2007) Effects of a carbohydrate-restricted diet with and without supplemental soluble fiber on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. Metab Clin Exp 56: 58–67
23. Paxman JR, Richardson JC, Dettmar PW et al. (2008) Daily ingestion of alginate reduces energy intake in free-living subjects. Appetite 51: 713–719
24. Odunsi ST, Vázquez-Roque MI, Camilleri M et al. (2010) Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity 18: 1579–1584
25. Georg Jensen M, Kristensen M, Astrup A (2011) Can alginate-based preloads increase weight loss beyond calorie restriction? A pilot study in obese individuals. Appetite 57: 601–604
26. Georg Jensen M, Kristensen M, Belza A et al. (2012) Acute effect of alginate-based preload on satiety feelings, energy intake, and gastric emptying rate in healthy subjects. Obesity (Silver Spring, Md.) 20: 1851–1858
27. Georg Jensen M, Kristensen M, Astrup A (2012) Effect of alginate supplementation on weight loss in obese subjects completing a 12-wk energy-restricted diet. A randomized controlled trial. AJCN 96: 5–13
28. Nürnberg E, Surmann P. Hagers Handbuch der pharmazeutischen Praxis. Methoden. 5., vollst. neubearb. Aufl., Springer, Berlin/London (1991)
29. Yavorska N (2012) Sodium alginate – a potential tool for weight management: effect on subjective appetite, food intake, and glycemic and insulin regulation. JLS 6: 66–69
30. Rimbach G, Möhring J, Erbersdobler HF. Lebensmittel-Warenkunde für Einsteiger. Springer, Heidelberg (2010)
31. Bollini R, Carnovale E, Campion B (1999) Removal of antinutritional factors from bean (Phaseolus vulgaris L.) seeds. Biotechnol Argron Soc 3: 217–219
32. Marshall JJ, Lauda CM (1975) Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, Phaseolus vulgaris. J Biol Chem 250: 8030–8037
33. Santimone M, Koukikolo R, Moreau Y et al. (2004) Porcine pancreatic alpha-amylase inhibition by the kidney bean (Phaseolus vulgaris) inhibitor (alpha-A11) and structural changes in the alpha-amylase inhibitor complex. Biochim Biophys Acta 1696: 181–190
34. Nicola P (2008) White bean extract. The Nutrition Practitioner 9: 44–47
35. Garrow JS, Scott PF, Heels S et al. (1983) „Starch blockers“ are ineffective in man. Lancet 1: 60–61
36. Udani J, Singh BB (2007) Blocking carbohydrate absorption and weight loss. A clinical trial using a proprietary fractionated white bean extract. Alternative Therapies 13: 32–37
37. Wu X, Xu X, Shen J et al. (2010) Enhanced weight loss from a dietary supplement containing standardized Phaseolus vulgaris extract in overweight men and women. J Appl Res 10: 73–79

38. Udani J, Hardy M, Madsen DC (2004) Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. *ALtern Med Rev* 9: 63–69
39. Celleno L, Tolaini MV, D'Amore A et al. (2007) A dietary supplement containing standardized *Phaseolus vulgaris* extract influences body composition of overweight men and women. *Int J Med Sci* 2007: 45–52
40. Grube B, Chong W, Chong P et al. (2014) Weight reduction and maintenance with IQP-PV-101. A 12-week randomized controlled study with a 24-week open label period. *Obesity* 22: 645–651
41. van der Poel AFD (1990) Effect of processing on antinutritional factors and protein nutritional value of dry bean (*Phaseolus vulgaris* L.). A review. *Anim Feed Sci Technol* 29: 179–208
42. Brudnak M (2002) Weight-loss drugs and supplements. Are there safer alternatives? *Medical Hypotheses* 58: 28–33
43. Montoya CA, Leterme P, Victoria NF et al. (2008) Susceptibility of phaseolin to in vitro proteolysis is highly variable across common bean varieties (*Phaseolus vulgaris* L.). *J Agric Food Chem* 56: 2183–2191
44. Boniglia C, Carratù B, Di Stefano S et al. (2008) Lectins, trypsin and α -amylase inhibitors in dietary supplements containing *Phaseolus vulgaris*. *Eur Food Res Technol* 227: 689–693
45. Barrett ML, Udani JK (2011) A proprietary α -amylase inhibitor from white bean (*Phaseolus vulgaris*): a review of clinical studies on weight loss and glycemic control. *Nutr J* 10: 24
46. Kumar S, Verma AK, Das M et al. (2013) Clinical complications of kidney bean (*Phaseolus vulgaris* L.) consumption. *Nutrition* 29: 821–827
47. Fischer T, Bordewick-Dell U (2015) Allergenes Potential von handelsüblichen Abnehmprodukten auf Basis von Chitosan und Bohnenextrakten (*Phaseolus vulgaris* L.). *Aktuel Ernährungsmed* 40: P1_3
48. Kumar R (1999) Chitin and chitosan fibres: A review. *Bull Mater Sc* 22: 905–915
49. Honarkar H, Barikani M (2009) Applications of biopolymers I. Chitosan. *Monatsh Chem* 140: 1403–1420
50. Muzzarelli RAA (1999) Chitosan-based dietary foods. *Carbohydrate Polymers* 29: 309–316
51. Stintzing FC, Carle R (2005) Cactus stems (*Opuntia* spp.): a review on their chemistry, technology, and uses. *Mol Nutr Food Res* 49: 175–194
52. Majdoub H, Roudesli S, Deratani A (2001) Polysaccharides from prickly pear peel and nopals of *Opuntia ficus-indica*: extraction, characterization and polyelectrolyte behavior. *Polymer International* 50: 552–560
53. Stintzing FC, Schieber A, Carle R (2001) Phytochemical and nutritional significance of cactus pear. *Eur Food Res Tech* (212): 396–407
54. Mhurchu CN, Poppitt SD, McGill A et al. (2004) The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. *Int J Obes Relat Metab Disord* 28: 1149–1156
55. Pittler MH, Abbot NC, Harkness EF et al. (1999) Randomized, double-blind trial of chitosan for body weight reduction. *Eur J Clin Nutr* 53: 379–381
56. Gades MD, Stern JS (2005) Chitosan supplementation and fat absorption in men and women. *J Am Diet Assoc* 105: 72–77
57. Schiller RN, Barrager E, Schauss AG et al. (2001) A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. *JANA* 4: 42–49
58. Kaats GR, Michalek JE, Preuss HG (2006). Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. *JACN* 25: 389–394
59. Liao F, Shieh M, Chang N et al. (2007) Chitosan supplementation lowers serum lipids and maintains normal calcium, magnesium, and iron status in hyperlipidemic patients. *Nutr Res* 27: 146–151
60. Trivedi VR, Satia MC, Deschamps A et al. (2016) Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction. *Nutr J* 15: 11
61. Grube B, Chong P, Lau K et al. (2013) A natural fiber complex reduces body weight in the overweight and obese. A double-blind, randomized, placebo-controlled study. *Obesity* 21: 58–64
62. Uebelhack R, Busch R, Alt F et al. (2014) Effects of cactus fiber on the excretion of dietary fat in healthy subjects: a double blind, randomized, placebo-controlled, crossover clinical investigation. *Curr Ther Res Clin E* 76: 39–44
63. Xia W, Liu P, Zhang J et al. (2011) Biological activities of chitosan and chitooligosaccharides. *Food Hydrocolloids* 25: 170–179
64. Koide SS (1998) Chitin-Chitosan: Properties, benefits and risks. *Nutr Res* 18: 1091–1101
65. Manore MM (2012) Dietary supplements for improving body composition and reducing body weight: where is the evidence? *Int J Sport Nutr Exe* 22: 139–154
66. Haaz S, Fontaine KR, Cutter G et al. (2006) Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. *Obes Rev* 7: 79–88
67. Rossato LG, Costa VM, Limberger RP et al. (2011) Synephrine. From trace concentrations to massive consumption in weight-loss. *Food Chem Toxicol* 49: 8–16
68. Hansen DK, George NI, White GE et al. (2013) Cardiovascular toxicity of citrus aurantium in exercised rats. *Cardiovasc Toxicol* 13: 208–219
69. Colker CM, Kalman DS, Torina GC et al. (1999) Effects of Citrus aurantium extract, caffeine, and St. John's Wort on body fat loss, lipid levels, and mood states in overweight healthy adults. *Curr Ther Res* 60: 145–153
70. Armstrong WJ, Johnson P, Duhme S (2001) The effect of commercial thermogenic weight loss supplement on body composition and energy expenditure in obese adults. *J Exp Physiol* 56: 290–299
71. Bundesinstitut für Risikobewertung (BfR) (2012) Gesundheitliche Bewertung von synephrin- und koffeinhaltigen Sportlerprodukten und Schlankheitsmitteln. *Stellungnahme Nr. 004/2013*
72. Mattoli L, Cangi F, Maidecchi A et al. (2005) A rapid liquid chromatography electrospray ionization mass spectrometry(n) method for evaluation of synephrine in Citrus aurantium L. samples. *J Agr Food Chem* 53: 9860–9866
73. Pellati F, Benvenuti S (2007) Fast high-performance liquid chromatography analysis of phenethylamine alkaloids in Citrus natural products on a pentafluorophenylpropyl stationary phase. *J Chromatography A* 1165: 58–66
74. Balthes W. *Lebensmittelchemie. 6., vollst. überarb. Aufl.*, Springer, Berlin/Heidelberg (2007)
75. Bui LT (2005) Blood pressure and heart rate effects following a single dose of Bitter Orange. *Annals Pharmacother* 40: 53–57
76. Stohs SJ, Preuss HG, Shara M (2012) A review of the human clinical studies involving Citrus aurantium (Bitter Orange) extract

- and its primary protoalkaloid *p*-synephrine. *Int J Med Sci* 9: 527–538
77. Retamero C, Rivera T, Murphy K (2011) "Ephedra-Free" diet pill-induced psychosis. *Psychosomatics* 52: 579–582
78. Bormann E (Hg). Rote Liste 2014. Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte) 54. Ausg., Verlag Rote Liste Service, Frankfurt (2014)
79. Angriff auf Dr. Slym. URL: www.apotheke-adhoc.de/nachrichten/markt/nachricht-detail-markt/schlankheitsmittel-angriff-auf-dr-slym/ Zugriff 27.06.16
80. XLS-MEDICAL MAX STRENGTH | XL-S Medical - Germany. URL: www.xlsmedical.de/xlsmedical/max-strength Zugriff 27.06.16
81. Grube B, Bongartz U, Alt F (2015) IQP-VV-102, a novel proprietary composition for weight reduction: a double-blind randomized clinical trial for evaluation of efficacy and safety. *eCAM* 2015
82. EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel). (2010) Scientific opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose. *EFSA Journal* 8: 27 p.
83. EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel). (2011) Scientific opinion on the substantiation of health claims related to chitosan and reduction in body weight (ID 679, 1499), maintenance of normal blood LDL-cholesterol concentrations (ID 4663), reduction of intestinal transit time (ID 4664) and reduction. *EFSA Journal* 9: 21 pp
84. EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel). (2011) Scientific opinion on the substantiation of health claims related to phaseolamine and reduction in body weight (ID 1701) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA Journal* 9: 13 pp
85. Stiftung Warentest (2014) Da helfen keine Pillen. *Schlankheitsmittel. test* (2): 20–25

DOI: 10.4455/eu.2016.044